Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Anat Rec (Hoboken) ; 296(8): 1148-53, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23728917

ABSTRACT

Intracortical bone remodeling is persistent throughout life, leading to age related increases in osteon population density (OPD). Intracortical porosity also increases with age in many mammals including humans, contributing to bone fragility and fracture risk. Unbalanced bone resorption and formation during disuse (e.g., physical inactivity) also increases intracortical porosity. In contrast, hibernating bears are a naturally occurring model for the prevention of both age-related and disuse osteoporoses. Intracortical bone remodeling is decreased during hibernation, but resorption and formation remain balanced. Black bears spend 0.25-7 months in hibernation annually depending on climate and food availability. We found longer hibernating bears demonstrate lower OPD and higher cortical bone mineralization than bears with shorter hibernation durations, but we surprisingly found longer hibernating bears had higher intracortical porosity. However, bears from three different latitudes showed age-related decreases in intracortical porosity, indicating that regardless of hibernation duration, black bears do not show the disuse- or age-related increases in intracortical porosity which is typical of other animals. This ability to prevent increases in intracortical porosity likely contributes to their ability to maintain bone strength during prolonged periods of physical inactivity and throughout life. Improving our understanding of the unique bone metabolism in hibernating bears will potentially increase our ability to develop treatments for age- and disuse-related osteoporoses in humans.


Subject(s)
Bone Density/physiology , Femur/physiology , Haversian System/physiology , Hibernation/physiology , Ursidae/physiology , Aging/pathology , Aging/physiology , Animals , Bone Remodeling/physiology , Bone Resorption/physiopathology , Femur/anatomy & histology , Florida , Haversian System/anatomy & histology , Male , Models, Animal , Osteogenesis/physiology , Porosity , Time Factors , Ursidae/anatomy & histology , Utah , West Virginia
2.
Bone ; 51(3): 578-85, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22584007

ABSTRACT

Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease that has deleterious consequences in muscle and bone, leading to decreased mobility, progressive osteoporosis, and premature death. Patients with DMD experience a higher-than-average fracture rate, particularly in the proximal and distal femur and proximal tibia. The dystrophin-deficient mdx mouse is a model of DMD that demonstrates muscle degeneration and fibrosis and osteoporosis. Parathyroid hormone, an effective anabolic agent for post-menopausal and glucocorticoid-induced osteoporosis, has not been explored for DMD. Black bear parathyroid hormone (bbPTH) has been implicated in the maintenance of bone properties during extended periods of disuse (hibernation). We cloned bbPTH and found 9 amino acid residue differences from human PTH. Apoptosis was mitigated and cAMP was activated by bbPTH in osteoblast cultures. We administered 28nmol/kg of bbPTH 1-84 to 4-week old male mdx and wild type mice via daily (5×/week) subcutaneous injection for 6 weeks. Vehicle-treated mdx mice had 44% lower trabecular bone volume fraction than wild type mice. No changes were found in femoral cortical bone geometry or mechanical properties with bbPTH treatment in wild type mice, and only medio-lateral moment of inertia changed with bbPTH treatment in mdx femurs. However, µCT analyses of the trabecular regions of the distal femur and proximal tibia showed marked increases in bone volume fraction with bbPTH treatment, with a greater anabolic response (7-fold increase) in mdx mice than wild type mice (2-fold increase). Trabecular number increased in mdx long bone, but not wild type bone. Additionally, greater osteoblast area and decreased osteoclast area were observed with bbPTH treatment in mdx mice. The heightened response to PTH in mdx bone compared to wild type suggests a link between dystrophin deficiency, altered calcium signaling, and bone. These findings support further investigation of PTH as an anabolic treatment for DMD-induced osteoporosis.


Subject(s)
Anabolic Agents/pharmacology , Bone and Bones/drug effects , Dystrophin/deficiency , Parathyroid Hormone/pharmacology , Ursidae/metabolism , Amino Acid Sequence , Animals , Anthraquinones/metabolism , Apoptosis/drug effects , Biomechanical Phenomena/drug effects , Bone and Bones/diagnostic imaging , Cell Line , Cyclic AMP/biosynthesis , Dystrophin/metabolism , Femur/diagnostic imaging , Femur/drug effects , Humans , Male , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/metabolism , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Organ Size/drug effects , Parathyroid Hormone/chemistry , Staining and Labeling , Tibia/diagnostic imaging , Tibia/drug effects , X-Ray Microtomography
SELECTION OF CITATIONS
SEARCH DETAIL